Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13436)	1/17/1998 10:15:00 PM
From: DrJerry	Read Replies (4) \| Respond to of 32384

Henry: HALLELUJAH! I just returned from a glorious ski trip and found the NY Times with its bio-tech article waiting for me- finally IR seems to have been able to get some word out-- I attended a conference ( in between downhill runs) and found: (1) diabetes was the most frequent topic - especially its cardiovascular complications (2) The general consensus around the country was that there would be no curtailing of the use of Rezulin (3) Everyone was aware of Glaxo's development of a similar TZD drug and the consensus was that it was a "cheap shot"to pull from UK market. (4) WHile it was fairly common knowledge that ERGO approval was soon, most cardiovascular specialists had reservations about the market share due to previous experience with bromocriptine and (5) Almost NOONE had any knowledge of LIGAND or of the use of rexinoids in diabetes. ADmittedly these were "satchel carriers" for the most part and not basic scientists but I still felt that IR needed to do a better job of public education. Also, there were some mutual fund people in attendance and I was amazed to find several biotech stocks on their lists that IMHO can't approach Lgnd for long term value. At any rate today's article is encouraging and I think I'll stock up on some more LGNDW. HENRY: How about speaking to a group of physicians at a conference in a major ski resort? It would probably due more for LGND stock price than IR's efforts!